---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004587"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:10:22.343895+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx preliminary 2024 revenue $555-560M above guidance; 2025 guide $640-670M

## Summary
- Preliminary 2024 total revenue $555-560M, exceeding top end of guidance, ~29% YoY growth.
- Crysvita revenue $405-410M (+24% YoY); Dojolvi revenue $87-89M (+25% YoY).
- 2025 total revenue guidance $640-670M; cash and investments ~$745M as of Dec 31, 2024.
- UX143 Phase 3 OI study second interim analysis mid-2025; GTX-102 Phase 3 Angelman enrollment completion H2 2025.
- UX111 BLA submitted (PDUFA H2 2025); DTX401 BLA filing mid-2025; DTX301 Phase 3 enrollment early 2025.

## SEC filing metadata
- accession: 0000950170-25-004587
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/0000950170-25-004587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017025004587/rare-20250112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004587
- JSON: https://secwatch.observer/filing/0000950170-25-004587.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.